SenzaGen AB ("SenzaGen" or the "Company") has today completed the acquisition of VitroScreen S.r.l. The acquisition took place in accordance with the agreement SenzaGen signed for the acquisition of VitroScreen S.r.l., which was announced on 28 October 2021.
VitroScreen is a recognized CRO and leading in vitro research laboratory with two decades experience committed to alternatives to animal testing within in vitro toxicology and pre-clinical testing. The transaction is in line with SenzaGen’s previously communicated accelerated growth strategy which includes acquisitions of profitable, growing companies that complement SenzaGen’s offering.
In accordance with the terms of the acquisition announced on 28 October 2021, the consideration consists in part of 416,586 consideration shares in SenzaGen, corresponding to approximately EUR 0.6 million at a subscription price of SEK 14.71 per share. The issuance of the consideration shares will increase the Company's share capital by SEK 20,829.30.
After the acquisition and the issue of consideration shares, the number of shares in SenzaGen will be 24,064,916, taking into account the directed share issue carried out on 29 October 2021.
Peter Nählstedt, CEO, SenzaGen AB
Email: firstname.lastname@example.org | Tel: +46 46 275 6201
Tina Dackemark Lawesson, VP Marketing & Communications
Email: email@example.com | Tel: +46 708-20 29 44
SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings. The company´s state-of-the-art GARD® test platform combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. Its high informational content and a holistic view of the immunological responses contribute to high predictive accuracy and human relevance. SenzaGen has its headquarters and GLP certified laboratory in Lund, Sweden, and a subsidiary in the US. For more information, please visit: www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North Growth Market (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, firstname.lastname@example.org, is the company’s Certified Adviser.